IDH1 and astrocytoma (excluding glioblastoma): Nine patients completed the protocol, and three of them were in a progression-free stage at 80, 64, and 62 months since diagnosis (all young, two of them with the IDH-1 mutation and one with a Grade III astrocytoma).